Who Paid My Doc
Megan Larson
Nurse Practitioner Boise, ID Nurse Practitioner
NPI 1861935660 CMS profile 2776315
287 W Jefferson St, Boise, ID 83702
General payments
$5,023
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Megan Larson of Boise, ID is reported in the CMS Open Payments database as having received $5,023 across 144 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 92nd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,558 | 53 | |
| 2024 | General | $2,127 | 53 | |
| 2023 | General | $1,044 | 32 | |
| 2021 | General | $294 | 6 |
Beside peers
- Megan Larson
- Nurse Practitioner median
- Middle half of Nurse Practitioner
- National median
In program year 2025, general payments to Megan Larson were reported at $1,558. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.
Show as a table
| Year | Megan Larson | Nurse Practitioner median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $50 | $22–$97 | $163 |
| 2020 | $0 | $40 | $16–$108 | $114 |
| 2021 | $294 | $135 | $40–$426 | $132 |
| 2022 | $0 | $152 | $48–$470 | $149 |
| 2023 | $1,044 | $166 | $54–$529 | $160 |
| 2024 | $2,127 | $173 | $55–$556 | $164 |
| 2025 | $1,558 | $174 | $55–$557 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 33 drugsPart D claims
2,922
Drug cost
$1,342,158
Branded share of claims
53.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 812 | $1,099,353 | |
| Xarelto Rivaroxaban | Brand | 130 | $155,454 | |
| Multaq Dronedarone Hcl | Brand | 27 | $38,413 | |
| Flecainide Acetate | Generic | 173 | $7,749 | |
| Sotalol Sotalol Hcl | Brand | 285 | $7,250 | |
| Diltiazem 24hr Er (Cd) Diltiazem Hcl | Brand | 158 | $6,768 | |
| Amiodarone Hcl | Generic | 206 | $6,253 | |
| Metoprolol Succinate | Generic | 359 | $5,137 | |
| Mexiletine Hcl | Generic | 24 | $3,021 | |
| Dabigatran Etexilate Dabigatran Etexilate Mesylate | Brand | 14 | $2,720 |
The 10 drugs with the highest cost, of 33 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 17 billing codesPaid by Medicare
$17,355
Medicare patients
309
Services billed
336
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Atrial fibrillation | 74% | |
| Arthritis | 51% | |
| Ischemic heart disease | 42% | |
| Heart failure | 41% | |
| Chronic kidney disease | 28% | |
| Diabetes | 26% | |
| Depression | 16% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
144 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Nurse Practitioner in Idaho
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner
Everyone recorded under this specialty, nationwide.
Doctors in Idaho
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.